TY - JOUR
T1 - Corrigendum
T2 - “Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)” (Annals of Oncology (2020) 31(1) (79–87), (S0923753419354055), (10.1016/j.annonc.2019.09.004))
AU - Kundranda, M.
AU - Gracian, A. C.
AU - Zafar, S. F.
AU - Meiri, E.
AU - Bendell, J.
AU - Algül, H.
AU - Rivera, F.
AU - Ahn, E. R.
AU - Watkins, D.
AU - Pelzer, U.
AU - Charu, V.
AU - Zalutskaya, A.
AU - Kuesters, G.
AU - Pipas, J. M.
AU - Santillana, S.
AU - Askoxylakis, V.
AU - Ko, A. H.
N1 - Publisher Copyright:
© 2020 European Society for Medical Oncology
PY - 2020/8
Y1 - 2020/8
N2 - The authors regret that Dr Bendell's disclosures were omitted from this publication. These disclosures are as follows: Dr. Bendell reports grants and other from Arrys Therapeutics, grants and other from BeiGene, grants and other from Boehringer Ingelheim, grants and other from Bristol-Myers Squibb, grants and other from Celgene, other from Cerulean, other from Daiichi Sankyo, grants and other from Evelo Biosciences, grants and other from Five Prime Therapeutics, other from FORMA Therapeutics, grants and other from Genentech, grants and other from Innate Pharma, other from Janssen, grants and other from Merck, grants and other from Merrimack Pharmaceuticals, other from Moderna Therapeutics, grants and other from Novartis, grants and other from Roche, grants and other from Seattle Genetics, grants and other from Taiho Oncology, other from Tolero Pharmaceuticals, other from Translational Drug Development, grants from Abbvie, grants from Stemcentrx, grants from ADC Therapeutics, grants from Agios, grants from Arcus Biosciences, grants from Array BioPharma, grants from AstraZeneca, grants from Bayer, grants from Bellicum Pharmaceuticals, grants from Bicycle Therapeutics, grants from Blueprint Medicine, grants from Boston Biomedical, grants from Calithera Biosciences, grants from Cyteir Therapeutics, grants from CytomX, grants from eFFECTOR Therapeutics, grants from Eisai, grants from Lilly, grants from EMD Serono, grants from Forty Seven, grants from Gilead Sciences, grants from Gossamer Bio, grants from Incyte, grants from Leap Therapeutics, grants from MacroGenics, grants from MedImmune, grants from Merus, grants from Millennium Pharmaceuticals, grants from NGM Biopharmaceuticals, grants from Novocure, grants from Oncologie, grants from OnocMed Pharmaceuticals, grants from Pieris Pharmaceuticals, grants from Revolution Medicines, grants and other from Rgenix, grants from SynDevRx, grants from Synthorx, grants from Takeda Pharmaceuticals, grants from Tarveda, grants from Tempest Therapeutics, grants from TRACON Pharmaceuticals, grants from Unum Therapeutics, outside the submitted work. The authors would like to apologise for any inconvenience caused.
AB - The authors regret that Dr Bendell's disclosures were omitted from this publication. These disclosures are as follows: Dr. Bendell reports grants and other from Arrys Therapeutics, grants and other from BeiGene, grants and other from Boehringer Ingelheim, grants and other from Bristol-Myers Squibb, grants and other from Celgene, other from Cerulean, other from Daiichi Sankyo, grants and other from Evelo Biosciences, grants and other from Five Prime Therapeutics, other from FORMA Therapeutics, grants and other from Genentech, grants and other from Innate Pharma, other from Janssen, grants and other from Merck, grants and other from Merrimack Pharmaceuticals, other from Moderna Therapeutics, grants and other from Novartis, grants and other from Roche, grants and other from Seattle Genetics, grants and other from Taiho Oncology, other from Tolero Pharmaceuticals, other from Translational Drug Development, grants from Abbvie, grants from Stemcentrx, grants from ADC Therapeutics, grants from Agios, grants from Arcus Biosciences, grants from Array BioPharma, grants from AstraZeneca, grants from Bayer, grants from Bellicum Pharmaceuticals, grants from Bicycle Therapeutics, grants from Blueprint Medicine, grants from Boston Biomedical, grants from Calithera Biosciences, grants from Cyteir Therapeutics, grants from CytomX, grants from eFFECTOR Therapeutics, grants from Eisai, grants from Lilly, grants from EMD Serono, grants from Forty Seven, grants from Gilead Sciences, grants from Gossamer Bio, grants from Incyte, grants from Leap Therapeutics, grants from MacroGenics, grants from MedImmune, grants from Merus, grants from Millennium Pharmaceuticals, grants from NGM Biopharmaceuticals, grants from Novocure, grants from Oncologie, grants from OnocMed Pharmaceuticals, grants from Pieris Pharmaceuticals, grants from Revolution Medicines, grants and other from Rgenix, grants from SynDevRx, grants from Synthorx, grants from Takeda Pharmaceuticals, grants from Tarveda, grants from Tempest Therapeutics, grants from TRACON Pharmaceuticals, grants from Unum Therapeutics, outside the submitted work. The authors would like to apologise for any inconvenience caused.
UR - http://www.scopus.com/inward/record.url?scp=85086035521&partnerID=8YFLogxK
U2 - 10.1016/j.annonc.2020.05.011
DO - 10.1016/j.annonc.2020.05.011
M3 - Comment/debate
C2 - 32507672
AN - SCOPUS:85086035521
SN - 0923-7534
VL - 31
SP - 1094
JO - Annals of Oncology
JF - Annals of Oncology
IS - 8
ER -
